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Abstract
Background: Spirometry is regarded as the gold standard for the diagnosis of COPD, yet the condition is widely
underdiagnosed. Therefore, additional screening methods that are easy to perform and to interpret are needed.
Recently, we demonstrated that low frequency ultrasound (LFU) may be helpful for monitoring lung diseases. The
objective of this study was to evaluate whether LFU can be used to detect air trapping in COPD. In addition, we
evaluated the ability of LFU to detect the effects of short-acting bronchodilator medication.
Methods: Seventeen patients with COPD and 9 healthy subjects were examined by body plethysmography and
LFU. Ultrasound frequencies ranging from 1 to 40 kHz were transmitted to the sternum and received at the back
during inspiration and expiration. The high pass frequency was determined from the inspiratory and the expiratory
signals and their difference termed ΔF. Measurements were repeated after inhalation of salbutamol.
Results: We found significant differences in ΔF between COPD subjects and healthy subjects. These differences
were already significant at GOLD stage 1 and increased with the severity of COPD. Sensitivity for detection of
GOLD stage 1 was 83% and for GOLD stages worse than 1 it was 91%. Bronchodilator effects could not be
detected reliably.
Conclusions: We conclude that low frequency ultrasound is cost-effective, easy to perform and suitable for
detecting air trapping. It might be useful in screening for COPD.
Trial Registration: ClinicalTrials.gov: NCT01080924
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Background
Chronic obstructive pulmonary disease (COPD) poses a
challenge to current and future health care systems. As
a result of increased tobacco consumption and demo-
graphic development, COPD is expected to become the
third leading cause of death worldwide by the year 2020
[1]. Early diagnosis and intervention is necessary to pre-
vent a further decline of lung function in these patients.
The Global Initiative for Chronic Obstructive Lung Dis-
ease (GOLD) recommends spirometry as the gold stan-
dard for the diagnosis of COPD, since it is the most
reproducible, standardized and objective way of
measuring airflow limitation [2]. However, to perform
spirometry, experienced and regularly trained medical
assistants are needed as well as physicians for interpret-
ing the results. Possibly due to these problems, spirome-
try is not frequently used by general practitioners and
underdiagnosis of COPD is widespread [3-8]. Therefore,
an additional screening method that is easier to perform
and to interpret is needed.
Conventional ultrasound with frequencies ranging
from 2 to 10 MHz is increasingly used for the diagnosis
of pulmonary diseases including pneumothorax, pleural
effusion, alveolar-interstitial syndrome and lung consoli-
dation. However, its application is restricted to superfi-
cial examination and to abnormally dense lungs [9-12].
The healthy lung cannot be visualized, because differ-
ences in acoustic impedances between aerated lung tis-
sue and pleural cavity cause total internal reflection [13].
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A novel approach to non-invasive monitoring of the
lungs is low frequency ultrasound spectroscopy [14].
Earlier, Goncharoff et al. described the sound transmis-
sion between 5 and 20 kHz from the mouth to the back
[15]. More recently, Rüter et al. applying frequencies
between 5 and 40 kHz to the sternum demonstrated
that the signals received at the back differed between
inspiration and expiration in healthy human subjects.
The sound spectra changed dependent on the lung aera-
tion: higher aeration resulted in a weaker signal and in a
shift of the high pass filter towards higher frequencies.
In contrast, in COPD patients the sound spectra during
inspiration and expiration remained unchanged [14].
During expiration the signal of COPD patients was simi-
lar to the inspiratory signal of healthy subjects, suggest-
ing that this method may be useful for detecting air
trapping. In that study, the area under the curve of the
sound spectra between 10 and 20 kHz correlated with
the forced expiratory volume in 1 sec (FEV1) and the
intrathoracic gas volume (ITGV) and differed signifi-
cantly between COPD and non-COPD subjects [14].
Air trapping is a critical clinical feature of COPD. The
objective of our study was to evaluate whether air trap-
ping in COPD patients can be detected reliably using
low frequency ultrasound (LFU). COPD patients were
classified into severity stages GOLD 1-3 [2] and were
examined by both body plethysmography and low fre-
quency ultrasound. The amplitude and the high pass
frequencies of the sound spectra were compared
between COPD patients and healthy subjects. Further-
more we analyzed the bronchodilator effect of salbuta-
mol by body plethysmography and frequency content.
Methods
Study subjects
Male or female subjects aged 18 to 70 years with a body
mass index ≤ 30 kg/m2 were eligible for the study. Sub-
jects with COPD had obstructive ventilatory dysfunction
and the typical symptoms of COPD according to the
GOLD guidelines [2]. Healthy subjects were included in
the study if they were nonsmokers with normal results
in spirometry (FEV1 > 80% of predicted and FEV1/FVC
≥ 70%) and no history of respiratory disease. Subjects
with respiratory tract infection within four weeks before
screening and subjects with medical conditions which
prohibit the use of salbutamol were excluded. The
Hannover Medical School institutional review board
approved the study and all patients gave written
informed consent.
Protocol
In a prospective cohort study patients with COPD and
healthy subjects were examined with low frequency
ultrasound before and after inhalation of salbutamol.
After written informed consent had been obtained, the
eligibility of subjects was assessed. Eligible subjects were
invited for the main study visit. On that day, body
plethysmography and low frequency ultrasound were
performed simultaneously before and 10-15 min after
inhalation of salbutamol. Bronchodilator use followed
the recommendations of the ATS/ERS task force [16].
Subjects with COPD inhaled 400 μg salbutamol while
healthy subjects received 200 μg salbutamol.
Low frequency ultrasound
The measurement setup is shown in Figure 1: A trans-
mitter with a diameter of 35 mm was attached to the
lower third of the sternum using an elastic thoracic belt.
Two piezoelectric receivers with a diameter of 40 mm
were placed on the back at the same height; the use of
gel was not necessary. Pulses were generated by a multi-
function data acquisition device NI USB-6251 (National
Instruments, Austin, TX, USA). The transmitted ultra-
sound pulses covered a spectrum from 1-40 kHz with a
transmit voltage amplitude of ± 15 V and a repetition
frequency of 800 Hz. The received signal was amplified
and sampled at 125 kHz, resulting in a 16 BIT digital
signal. In order to transform the original time function
into the frequency domain, a Fourier transform was
applied. Matlab (The MathWorks, Natick, MA, USA)
was used to control the device and to evaluate the data.
Figure 1 Measurement setup. Ultrasound pulses were generated
and transmitted to the sternum. After being received at the back
by two sensors, the signal was amplified and digitalized.
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Ultrasound measurements and lung function testing
were performed simultaneously. First the ultrasound sig-
nal was checked and the sensor position was corrected
if necessary. We made sure that we received an ade-
quate signal before beginning the measurements. After
starting the lung function testing, the ultrasound signals
were saved at the point of maximum inspiration, calm
maximum expiration and forced maximum expiration.
Ten minutes after inhaling salbutamol the measure-
ments were repeated.
The difference between inspiratory and expiratory fre-
quency content was evaluated, as shown in Figure 2.
The high pass frequency was determined from the
inspiratory and the expiratory signal, which corresponds
to the half value of the maximum receive voltage on a
logarithmic scale. Afterwards the difference between the
two high pass frequencies was calculated, giving the fre-
quency shift ΔF. We expected ΔF to increase in
response to salbutamol-induced bronchodilation. In
addition, we identified the amplitude of the expiratory
signal.
Statistics
IBM SPSS Statistics 18 for Windows (SPSS Inc., Chi-
cago, IL, USA) was used for statistical analysis. Because,
in a separate group of healthy individuals, we noted a
significant correlation between the body mass index
(BMI) and the inspiratory and expiratory signals (Addi-
tional file 1; Suppl. Figure 1), we used linear regression
to adjust the frequency signal of the following measure-
ments to a BMI of 26 kg/m2.
One-way analysis of variance (ANOVA) was used to
test for differences in lung function, frequency shift ΔF
and amplitude among the groups. Dunnett’s post-hoc
test was used to analyze differences between the healthy
control group and the three COPD groups. Equality of
variances was tested using Levene’s test; homoscedasti-
city was assumed if p > 0.01. To compare lung function
and frequency shift ΔF before and after bronchodilation,
a paired t-test was applied. P < 0.05 was considered sta-
tistically significant.
Results
Study subjects
Table 1 summarizes the characteristics of the study sub-
jects. Nine healthy subjects and 17 COPD patients were
included in the study. One patient was excluded because
of increased blood pressure at the screening visit; a
reserve patient participated in the trial instead. Three
patients with COPD were excluded due to technical rea-
sons. We assume that these subjects braced their
shoulders and backs intensely during breathing, thus
dislodging the sensors. We were able to reproduce their
Figure 2 Frequency spectra at inspiration and expiration. The
lowest frequency of the first strong amplitude signal was measured
during inspiration and expiration and the difference between these
frequencies was termed ΔF.
Table 1 Characteristics of healthy and COPD subjects
classified by GOLD stage I-III*
Characteristic Healthy
(n = 9)
GOLD 1
(n = 6)
GOLD 2
(n = 4)
GOLD 3
(n = 7)
age-yr 38.33 ± 9.72 52.83 ±
10.68
60.25 ± 9.50 59.14 ±
5.08
height-m 1.78 ± 0.06 1.78 ± 0.05 1.75 ± 0.09 1.75 ± 0.05
weight-kg 75.89 ±
11.20
81.50 ±
12.60
79.50 ±
14.27
77.29 ±
9.27
BMI-kg/m2 23.94 ± 3.07 25.62 ± 3.59 25.73 ± 2.36 25.33 ±
2.50
FEV1 - % pred.
pre
101.97 ±
9.36
82.55 ±
11.73
60.75 ± 4.40 31.94 ±
3.02
FEV1/FVC-% pre 75.99 ± 2.80 56.98 ± 5.89 47.43 ± 7.06 28.78 ±
4.83
R-kPa · s/l 0.18 ± 0.07 0.24 ± 0.07 0.34 ± 0.16 0.76 ± 0.31
ITGV-l 3.38 ± 0.56 4.93 ± 0.49 4.65 ± 0.46 6.23 ± 0.44
ITGV-% pred. 100.68 ±
13.31
139.12 ±
14.87
131.28 ±
16.49
176.70 ±
14.37
RV-l 1.84 ± 0.16 3.24 ± 0.56 3.32 ± 0.41 4.75 ± 0.62
RV-% pred. 96.16 ±
11.37
142.3 ±
15.22
139.15 ±
16.48
201.59 ±
26.75
FEV1 - % pred.
post
103.76 ±
9.37
89.47 ± 9.77 72.53 ± 3.40 37.54 ±
6.00
FEV1/FVC-%
post
77.53 ± 2.64 60.45 ± 5.04 52.06 ± 7.54 29.32 ±
6.03
* Plus-minus values are means ± SD. FEV1 and FEV1/FVC values are listed
before (prae) and after (post) application of salbutamol. There were significant
differences in age among healthy subjects and the three COPD groups, as
assessed with the use of one-way ANOVA and Dunnett’s post-hoc test (GOLD
1: p < 0.01, GOLD 2/GOLD3: p < 0.0001). In lung function testing, FEV1, FEV1/
FVC, ITGV and RV were significantly different (p < 0.0001) between healthy
and COPD subjects. Airway resistance (R) was significantly different between
healthy subjects and GOLD 3 (p < 0.0001).
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signals by intentionally shifting the sensors while record-
ing. Twenty-six patients completed the study.
Frequency shift ΔF
The frequency shift ΔF was compared between healthy
subjects and COPD patients. The measurements were
taken during body plethysmography in non-forced maxi-
mum breathing as well as during spirometry in forced
maximum breathing. During non-forced maximum
breathing, the average frequency shift of healthy subjects
was 8958 ± 2874 Hz. In contrast, frequency shifts of
COPD subjects were reduced to 58%, 43% and 37% for
GOLD 1, GOLD 2 and GOLD 3, respectively (Figure 3).
ΔF differed significantly between healthy and COPD
patients. The significance increased with the severity of
COPD with p = 0.023, p = 0.008 and p = 0.0007 for
GOLD 1,2 and 3, respectively.
During forced maximum breathing healthy subjects
achieved an average frequency shift of 7882 ± 3310 Hz.
As before, the frequency shifts of subjects with COPD
were reduced, with values of 59%, 72% and 45% in
GOLD 1-3, respectively (Figure 3). During forced maxi-
mum breathing, only COPD patients with severe COPD
(GOLD stage 3) showed significant differences in ΔF at
maximum inspiration and expiration compared to
healthy subjects (p = 0.0008).
One aim of this study was to evaluate the sensitivity
and specificity of LFU for detecting air trapping in
COPD. Therefore, we defined values below the 95%
confidence interval from the frequency shift of healthy
subjects as being indicative of air trapping (Table 2). As
the sample size was small in GOLD stage 2, for this cal-
culation subjects with GOLD 2 and 3 were combined.
During non-forced breathing air trapping was recog-
nized in 5 of 6 COPD patients with GOLD stage 1 and
in 10 of 11 patients with GOLD stages 2 and 3. Sensitiv-
ity for GOLD 1 was 83.3% and 90.9% for GOLD 2/3, the
specificity for detection of air trapping of any stage was
88.9%. During forced breathing the LFU method was
less effective (Table 2).
Amplitude
In healthy individuals, the maximum amplitude from the
expiratory frequency spectrum was -35.2 ± 29.1 dB.
Values in COPD patients were reduced to -44.8 ± 34.5
dB in GOLD 1, -64.3 ± 30.8 dB in GOLD 2 and -52.7 ±
30.0 dB in GOLD 3. Statistical analysis of the amplitude
data in a one-way ANOVA with Dunnett’s post-hoc test
showed no significant difference from healthy subjects
for any of the GOLD stages. Furthermore, the area
under the curve was calculated in the interval of 10 to
Figure 3 Frequency shift ΔF at maximum inspiration and expiration. Frequency shifts ΔF were compared between healthy subjects (n = 9)
and COPD subjects classified by GOLD (GOLD 1: n = 6, GOLD 2: n = 4, GOLD 3: n = 7). a) During non-forced maximum breathing, one-way
ANOVA and Dunnett’s post-hoc test showed significant differences between healthy subjects and each GOLD stage. Significance increased from
GOLD 1 to GOLD 3 (GOLD 1: p = 0.023, GOLD 2: p = 0.008, GOLD 3: p = 0.0007). b) During forced maximum breathing, there was a significant
difference between healthy subjects and GOLD stage 3 at p = 0.0008.
Table 2 Sensitivity for detection of air trapping
Sensitivity [%]
Non-forced breathing
Sensitivity [%]
Forced breathing
GOLD 1 83.3 66.7
GOLD 2 + 3 90.9 72.2
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20 kHz. Values in healthy subjects and GOLD 1 were
almost identical, while values in GOLD 2 and GOLD 3
were reduced. In one-way ANOVA with Dunnett’s post-
hoc test the AUC values from GOLD 3 patients were
again significantly different from those of healthy sub-
jects (p = 0.031) [14].
Bronchodilator response
After inhalation of salbutamol, the measurements of
lung function testing and ultrasound were compared to
the original values (Figure 4). The forced expiratory
volume in the first second (FEV1) increased by 1.75% in
healthy subjects, by 8.38% in GOLD stage 1, by 19.38%
in GOLD stage 2 and by 17.53% in GOLD stage 3. Air-
way resistance (R) decreased by 22.3% in healthy sub-
jects, by 22.8% in GOLD stage 1, by 37.3% in GOLD
stage 2 and by 32.1% in GOLD stage 3. Residual volume
(RV) increased by 5.1% in healthy subjects and
decreased by 11% in GOLD stage 1, by 10.7% in GOLD
stage 2 and by 12.4% in GOLD stage 3. During non-
forced maximum breathing, the frequency shift (ΔF)
increased by 4% in healthy subjects. In COPD patients it
increased by 16% for GOLD stage 1, by 48% in GOLD
stage 2 and by 56% in GOLD stage 3. However, this
increase in ΔF in response to salbutamol-induced
bronchodilation was not significantly different in any of
the groups. During forced maximum breathing the fre-
quency shift increased by 12% in healthy subjects. Sub-
jects with GOLD stage 1 disease had the greatest
increase of 46%, while frequency shifts of patients with
GOLD stage 2 and 3 disease increased by 17% and 24%,
respectively. As in non-forced breathing, these increases
were not significant in any group.
Safety
There were no adverse events reported in this study.
Discussion
Despite the fact that the physics of low frequency ultra-
sound are not fully understood, this study shows that air
trapping in COPD can be detected by LFU. We found
significant differences in ΔF between healthy subjects
Figure 4 Lung function and ultrasound before and after inhalation of Salbutamol. a) FEV1 increased significantly in healthy and COPD
subjects (healthy: p = 0.01, GOLD 1: p = 0.011, GOLD 2: p = 0.015, GOLD 3: p = 0.012). b) Airway resistance decreased significantly in healthy
subjects (p = 0.0002) as well as in GOLD stage 1 (p = 0.005) and GOLD stage 3 (p = 0.032). c) Residual volume decreased significantly in healthy
subjects (p = 0.033) as well as in GOLD stage 1 (p = 0.016) and GOLD stage 3 (p = 0.02). d) There was no significant difference of frequency
shift during non-forced maximum breathing in any group.
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and COPD subjects during maximum inspiration and
expiration. These differences were already significant at
GOLD stage 1 and increased with the severity of COPD.
The sensitivity for detecting GOLD stage 1 was 83.3%,
for detecting moderate to severe COPD (GOLD 2 and
3) it was 90.9%. Our sensitivity analysis (Table 2)
showed that these measurements should be obtained
during unforced maximum breathing.
Spirometry is required to make the diagnosis of
COPD; the presence of a post-bronchodilator FEV1/FVC
< 0.70 confirms the presence of persistent airflow reduc-
tion and thus of COPD according to the GOLD guide-
line recommendations [2]. Although there is currently
insufficient evidence to recommend routine use of low
frequency ultrasound, this additional measurement may
help to disclose the degree of air trapping in patients
with COPD. The method may also be useful in cases
where body plethysmography or comparable techniques
are unavailable.
In contrast to previous work we found no significant
differences in the signal amplitude between COPD
patients and healthy subjects [14]. This may be
explained by the subject selection, because Rüter et al.
examined a group of patients with mainly very severe
COPD (GOLD stage 4) [14], while we examined COPD
patients with GOLD stages 1 to 3. In principle, however,
the present study confirms the previous findings [14].
As expected, ΔF increased in response to bronchodila-
tion, but these results were not significant. In contrast,
bronchodilation as measured by spirometry and by body
plethysmography was associated with a significant
increase of FEV1 and a significant decrease of airway
resistance, respectively. Thus, these conventional mea-
sures are more suitable than LFU for assessing broncho-
dilator responses.
As mentioned above, it is still unclear how low fre-
quency ultrasound is transmitted through the human
thorax. Rüter et al. showed that with increasing air con-
tent of the lungs during inspiration the high pass fre-
quency increased while the signal amplitude decreased.
It was suggested that sound traveling through the lungs
was influenced by differences in lung density [14]. An
important finding in our study was that the typical
expiratory signal was received above the abdominal tis-
sue of a healthy person. When placing the sensor above
the lower lung border, the signal changed from an
expiratory signal with high amplitude and low high-pass
frequency during expiration, to an inspiratory signal
with lower amplitude and higher high-pass frequency
during inspiration. These results can be explained if we
assume that the signal is traveling through the abdom-
inal tissue and is attenuated and filtered by the lung,
moving into the signal pathway during inspiration. Such
a pathway would also explain the dependency on the
BMI (Additional file 1; Suppl. Figure 1), because abdom-
inal fat tissue is expected to transmit sound signals well.
Thus, the movement of the diaphragm may be the rea-
son for the frequency variability. In COPD hyperinfla-
tion of the lungs leads to lowering of the diaphragm and
to straightening of the diaphragmatic domes while dia-
phragmatic movement is reduced [17-19]. Rüter et al.
described the expiratory signal of a COPD subject as
resembling the inspiratory signal of a healthy person
[14]. Airway obstruction of COPD patients limits their
ability to exhale. This would explain why these patients
are not able to achieve the expiratory diaphragmatic
position of healthy subjects, resulting in an attenuated
signal containing higher frequencies. Accordingly, the
frequency variability in COPD patients was less pro-
nounced than in healthy subjects and decreased with air
trapping.
At present, the LFU method has a number of limita-
tions that need further clarification. It remains uncertain
whether the method can be applied to obese patients, as
sound transmission through the subcutaneous tissue
cannot be excluded. Our studies showed that the signal
of subjects with increased body mass index was of
higher amplitude than in patients with normal weight.
Age, however, does not appear to affect the signal,
because a covariate analysis failed to detect age as a fac-
tor influencing the LFU signals. However, further studies
to define the effect of age and gender are needed. It
appears that the necessary degree of cooperation may be
less than with conventional FEV1 measurements
because meaningful measurements are possible with
non-forced maximum expiration. Why the LFU method
was even more sensitive with non-forced as opposed to
forced expiration breathing is unclear at present;
whether this might be explained by the speed and dis-
tortion of the chest wall displacement needs to be
determined.
Conclusions
In summary, we have shown that low frequency ultra-
sound is able to detect air trapping in COPD patients
of GOLD stage 1-3 and appears to be a useful addi-
tional tool in the screening for COPD. It is inexpen-
sive, easy to perform and noninvasive, so it could be
applied during routine checks in general practice medi-
cine to monitor air trapping. In contrast to spirometry
and body plethysmography, no special training is
required. We conclude that low frequency ultrasound
might be helpful in identifying air trapping and in
deciding which patients should undergo more specia-
lized lung function testing. We suggest that further
studies with more study subjects should be performed
to define reference values and to further standardize
the measuring procedure.
Morenz et al. BMC Pulmonary Medicine 2012, 12:8
http://www.biomedcentral.com/1471-2466/12/8
Page 6 of 7
Additional material
Additional file 1: Supplementary figure. 1 Relationship between
BMI and the inspiratory and the expiratory signals. The high pass
frequencies were determined for inspiration (circle) and the expiration
(triangle). Linear regression analysis showed the following correlation
between the BMI and the high pass frequencies: r2 inspiration: 0.29 (p =
0.0046); r2 expiration: 0.66 (p < 0.0001).
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